se experience of tolvaptan for end stage liver disease waiting for liver transplantation.
Not Applicable
- Conditions
- end stage liver disease
- Registration Number
- JPRN-UMIN000027096
- Lead Sponsor
- The University of Tokyo Hepato-biliary-pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1.poor oral intake 2.past history to administrate tolvaptan 3.rejection by patients
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method change of body weight after initiation
- Secondary Outcome Measures
Name Time Method urine volume,total-bilirubin,creatinine,sodium,Child-Pugh score,MELD score,Clavien-Dindo score,post operative day,readmission